SESSION TYPE: Lung Cancer Posters I
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM
PURPOSE: To demonstrate how EarlyCDT®-Lung, a blood test that detects the presence of autoantibodies to tumor-associated antigens, has benefited our pulmonology practice in detecting lung cancer. Reported here is a review of the clinical outcomes for our first 70 patients to have been tested by EarlyCDT-Lung.
METHODS: Seventy patients seen in our high risk (for lung cancer) clinic who were tested by EarlyCDT-Lung and consented for their medical records to be shared with Oncimmune® are being reported here. Patients deemed high risk, based on their age, smoking history and/or the presence of a suspicious CT-identified pulmonary lesion, were referred for the blood test. The average 5-year risk of lung cancer (based on age and smoking history alone) for all patients was calculated to be 4.4%. All lung cancers were diagnosed within 6 months of the EarlyCDT-Lung test.
RESULTS: Twelve patients were found to be Positive for at least one lung cancer-associated autoantibody elevated above the clinical cut-off for EarlyCDT-Lung, and 56 tested Negative. Six patients who tested Positive and 9 patients who tested Negative were found to have lung cancer, showing 40% (6/15) sensitivity for lung cancer and specificity of 89% (47/53). Four of the 6 patients (67%) who tested positive and were diagnosed with lung cancer were found at early stage. The positive predictive value was 6/12 (1 in 2), revealing that a Positive EarlyCDT-Lung result significantly increases our patients’ risk for lung cancer.
CONCLUSIONS: In our clinic, EarlyCDT-Lung has performed as reported in Oncimmune’s publications. The majority of cancers detected were at early stage. The high positive predictive value makes it a good complement to CT in the cases where a patient is found to have a suspicious pulmonary nodule.
CLINICAL IMPLICATIONS: EarlyCDT-Lung has been, and continues to be, a valuable tool used in our practice for evaluating a patient’s risk for lung cancer, for patients with a CT-identified pulmonary nodule as well as those with an extensive smoking history.
DISCLOSURE: The following authors have nothing to disclose: Richard Kucera
No Product/Research Disclosure InformationPulmonary & Critical Care Associates, Greensburg, PA